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Abstract
Endocannabinoids (eCBs) inhibit neurotransmitter release throughout the central nervous system. Using the Ceratomandibularis
muscle from the lizard Anolis carolinensis we asked whether eCBs play a similar role at the vertebrate neuromuscular junction. We
report here that the CB1 cannabinoid receptor is concentrated on motor terminals and that eCBs mediate the inhibition of
neurotransmitter release induced by the activation of M3 muscarinic acetylcholine (ACh) receptors. N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide, a CB1 antagonist, prevents muscarine from inhibiting
release and arachidonylcyclopropylamide (ACPA), a CB1 receptor agonist, mimics M3 activation and occludes the effect of
muscarine. As for its mechanism of action, ACPA reduces the action-potential-evoked calcium transient in the nerve terminal and this
decrease is more than sufﬁcient to account for the observed inhibition of neurotransmitter release. Similar to muscarine, the inhibition
of synaptic transmission by ACPA requires nitric oxide, acting via the synthesis of cGMP and the activation of cGMP-dependent
protein kinase. 2-Arachidonoylglycerol (2-AG) is responsible for the majority of the effects of eCB as inhibitors of phospholipase C
and diacylglycerol lipase, two enzymes responsible for synthesis of 2-AG, signiﬁcantly limit muscarine-induced inhibition of
neurotransmitter release. Lastly, the injection of (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (an
inhibitor of eCB transport) into the muscle prevents muscarine, but not ACPA, from inhibiting ACh release. These results collectively
lead to a model of the vertebrate neuromuscular junction whereby 2-AG mediates the muscarine-induced inhibition of ACh release.
To demonstrate the physiological relevance of this model we show that the CB1 antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide prevents synaptic inhibition induced by 20 min of 1-Hz stimulation.
Introduction
Cannabinoids, the active ingredients found in the marijuana plant
Cannabis sativa (Ameri, 1999; Martin et al., 1999), produce their
biological effects through binding to speciﬁc G-protein-coupled
receptors (Howlett et al., 2002). The term endocannabinoid (eCB)
refers to endogenously released compounds that alter function by
binding to these receptors (Devane et al., 1992; Evans et al., 1992).
The eCBs are synthesized de novo from membrane phospholipids and
are released through an unknown mechanism (Freund et al., 2003; but
see Ronesi et al., 2004). Recently, eCBs have been shown to act as
retrograde signalling molecules in several areas of the central nervous
system (for reviews see Kreitzer & Regehr, 2002; Wilson & Nicoll,
2002). Depolarization of the postsynaptic neurone and the resulting
elevation of intracellular Ca
2+ triggers eCB release (Ohno-Shosaku
et al., 2001; Wilson & Nicoll, 2001; Brenowitz & Regehr, 2003). The
activation of muscarinic acetylcholine (ACh) receptors (mAChRs)
(Kim et al., 2002; Ohno-Shosaku et al., 2003; Fukudome et al., 2004)
can also trigger the release of eCBs. The eCBs released in neural tissue
usually bind to the CB1 receptor subtype and inhibit the release of
neurotransmitter from the presynaptic terminal (Kreitzer & Regehr,
2001, 2002; Maejima et al., 2001; Ohno-Shosaku et al., 2001; Wilson
& Nicoll, 2001; Diana et al., 2002; Yoshida et al., 2002; but see
Van Sickle et al., 2005).
The inhibition of neurotransmitter release via the activation of
mAChRs has been observed throughout both the central and
peripheral nervous systems (for reviews, see Starke et al., 1989;
Caulﬁeld, 1993; Boehm & Huck, 1997). It has been well established
that activation of mAChRs at the vertebrate neuromuscular junction
(NMJ) modulates the release of the neurotransmitter ACh (Ganguly &
Das, 1979; Duncan & Publicover, 1979; Michaelson et al., 1979;
Standaert, 1982; Wali et al., 1988; Slutsky et al., 1999, 2001; Minic
et al., 2002). In particular, activation of the M1 subtype of the mAChR
enhances ACh release (Slutsky et al., 1999; Graves et al., 2004),
whereas activation of the M2 and⁄or M3 subtype inhibits release
(Slutsky et al., 1999, 2001; Graves et al., 2004). Recently, the
M1-mediated enhancement and the M3-mediated inhibition of neuro-
transmitter release at the lizard NMJ have been shown to require the
synthesis and extracellular diffusion of nitric oxide (NO) (Graves
et al., 2004).
As eCBs mediate the suppression of neurotransmitter release
induced by M1 and M3 receptor activation in the hippocampus
(Fukudome et al., 2004), we searched for a similar involvement of
eCBs at the lizard NMJ. Using immunoﬂuorescence, we localized CB1
receptors to the NMJ and, using physiological and pharmacological
approaches, discovered that eCBs [primarily 2-arachidonoylglycerol
(2-AG)] do indeed mediate the depression of neurotransmitter release
induced by the activation of M3 mAChRs. Furthermore, this
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protein kinase, involves a decrease in the size of the calcium transient
in the presynaptic nerve terminal, and requires an eCB transporter in
the muscle membrane. Lastly, we demonstrate the physiological
relevance of eCBs by showing that a form of long-term synaptic
depression requires functional CB1 receptors.
Materials and methods
Experimental preparation and solutions
Prior to being pithed, lizards (Anolis carolinensis; Carolina Biological
Supply Co.) were placed at 7–10  C for 8–10 min to facilitate the
quick and accurate ablation of the forebrain. The ceratomandibularis
muscle (and its associated nerve) was isolated from small lizards as
described by Lindgren & Moore (1989) and pinned down in a
Sylgard
 -coated chamber containing fresh physiological saline
solution composed of 158 mm NaCl, 2 mm KCl, 2 mm MgCl2,
5m m HEPES, 2 mm CaCl2 and 2 g⁄L dextrose (pH adjusted to 7.3
using 1 m NaOH). Evoked end-plate potentials (EPPs) were reduced
below the action potential threshold of the muscle by applying 10 lm
d-tubocurarine chloride. For experiments indicated in Fig. 8, 2.5 lm
d-tubocurarine chloride was used together with 1 lg⁄mL tetraethylr-
hodamine-a-bungarotoxin The procedures described above were
approved by the Institutional Animal Use and Care Committee at
Grinnell College.
In all of the experiments except the one described in Fig. 8, drugs
were administered via the physiological saline solution bathing the
preparation. Unless indicated otherwise, concentrated stock solutions
of the various drugs were prepared in advance and frozen at )20  C.
On the day of the experiment, aliquots were diluted in physiological
saline solution to their ﬁnal concentrations. In the case of arachido-
nylcyclopropylamide (ACPA) or (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-
methylphenyl)-5,8,11,14-eicosatetraenamide (VDM 11), the drug was
obtained in Tocrisolve
  (a soy oil and water emulsion) and diluted
directly into physiological saline. In experiments where ACPA or
VDM 11 was applied, the control solution contained Tocrisolve
  at
the same concentration as in the experimental solution.
For the experiments depicted in Fig. 8, muscarine or ACPA was
applied locally to an identiﬁed NMJ through a glass pipette with a
diameter of approximately 1 lm via back pressure applied with a
pneumatic pico pump (PV 830; World Precision Instruments, Sarasota,
FL, USA). Between one and six 2- and 5-s pressure pulses (10 s apart)
were applied at 10–15 p.s.i. The electrode was ﬁlled with 20 lm
muscarine or ACPA and either rhodamine B or ﬂuorescein. The latter
were used to track the dispersion of the pipette contents. The electrode
was positioned within 100–200 lm of nerve terminals on the top
surface of the muscle and the dispersion of the dye always enveloped
the NMJ. Although we do not know the local concentration of
muscarine or ACPA at the synapse, the concentrations used produced
changes similar to bath application of either chemical.
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
potassium salt (carboxy-PTIO) was purchased from Molecular




a]quinoxalin-1-one (ODQ) and VDM 11 were purchased from Tocris
Cookson (Ellisville, MO, USA). 1,6-Bis-(cyclohexyloximinocarbonyl-
amino)-hexane (RHC-80267) was purchased from Biomol (Plymouth
Meeting, PA, USA). All other drugs, including 4-diphenylacetoxy-N-
methylpiperidine methiodide, Rp-b-phenyl-1,N2-etheno-8-bromo-
guanosine 3¢,5¢-cyclic monophosphorothioate (Rp-8-Br-PET-cGMPS),
diethylamine⁄NO complex and Nx-nitro-l-arginine methyl ester
(L-NAME),werepurchasedfromSigma-Aldrich(StLouis,MO,USA).
Immunoﬂuorescence
Muscles were ﬁxed in 3% paraformaldehyde for 1 h at 4  C, rinsed for
1 h in physiological saline, permeablized for 30 min at 37  C in 0.3%
TritonX-100, preincubated for 15 minatroom temperature (22–24  C)
in blocking solution (0.01% Triton X-100, 1% bovine serum albumin)
and incubated in primary antibody (10 lg⁄mL of rabbit anti-human
CB1 IgG no. 1; Alpha Diagnostic International, San Antonio, TX,
USA) for 4 h at room temperature and then 12 h at 4  C. Muscles
were rinsed for 1 h in blocking solution, incubated with ﬂuorescein-
conjugated goat anti-rabbit IgG secondary antibody (5 lg⁄mL;
American Qualex, San Clemente, CA, USA) for 2 h at 37  C, rinsed
in blocking solution for 30 min and mounted on slides with 20%
glycerol in Slowfade Antifade
  solution (Sigma-Aldrich). The antigen
used to create the primary antibody was a 14-amino-acid peptide,
referred to as CB11-P, which is found near the extracellular
N-terminus of human CB1 (CB11-A; Alpha Diagnostic International).
No punctate staining was observed when the secondary antibody was
applied without the primary antibody.
To visualize the perisynaptic Schwann cells (PSCs), preparations
were incubated for 15 min at room temperature with 1 lm POPO
 -3
iodide nucleic acid stain (Molecular Probes) following the wash of the
secondary antibody and then washed for 30 min in blocking solution.
To visualize nerve terminals, the ends of cut nerve axons were loaded
with Texas red dextran (Molecular Probes; 3000 MW, made in 10 mm
HEPES, pH 7.2). Immediately following isolation of the Ceratoman-
dibularis muscle and its associated nerve, the cut end of the nerve axon
was placed into a small (1–2 lL) well containing 20 mm Texas red
dextran. The Texas red dextran was allowed to load through antero-
grade transport at 9  C for 16–18 h and then at 4  C for an additional
2–3 h. After the nerve terminals had been ﬁlled with Texas red dextran,
the tissue was processed for immunoﬂuorescence as described above.
After being stained, NMJs were observed with a laser scanning
confocal microscope manufactured by Prairie Technologies (Middle-
ton, WI, USA) connected to a Nikon inverted microscope with a 60·
oil immersion objective (1.4 numerical aperture). Images were
manipulated and displayed using metamorph
  software (v6.3,
Universal Imaging, Downingtown, PA, USA).
Electrophysiology
End-plate potentials were evoked by stimulating the motor nerve axon
with a continuous train of depolarizing square pulses of 1–10 V,
0.04 ms duration, at 0.25 Hz (or, for the conditioning stimuli used in
Fig. 10, 1 Hz). EPPs were measured using glass micropipettes ﬁlled
with 3 m KCl (20–40 MW). Membrane potentials were ampliﬁed with
a Cell Explorer (Dagan Instruments, Minneapolis, MN, USA) and
collected with a MacLab data acquisition system (AD Instruments,
Colorado Springs, CO, USA). For the experiments depicted in Figs 2,
5, 6, 7 and 10, EPPs were recorded from randomly selected muscle
ﬁbers. Each trial (n) represents the mean EPP amplitude recorded at
ﬁve to eight locations (i.e. NMJs) in a single preparation. The
electrode was inserted in each muscle cell only long enough to record
between four and 16 EPPs that were ﬁltered to reject direct current (i.e.
16–64 s), which were averaged online and the maximum amplitude
measured ofﬂine. For the experiment depicted in Fig. 3, the
intracellular recording electrode was inserted into a single muscle
1620 Z. Newman et al.
ª The Authors (2007). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 25, 1619–1630ﬁbre and left in place long enough to record at least 100 miniature
EPPs (MEPPs) before and during the application of ACPA (approx.
10 min). For the experiments depicted in Fig. 8, the intracellular
electrode was ﬁlled with 1.5 m KCl (rather than 3 m KCl) and inserted
into a muscle cell just long enough to record between four and eight
EPPs (i.e. 8–32 s). The electrode was carefully retracted until it was
just outside the muscle. The electrode was then reinserted at the same
spot after waiting at least 1 min. This process was repeated up to 10
times. In these experiments, n refers to the number of muscle cells (i.e.
NMJs). Student’s t-test (two-sample assuming equal variance) was
used to evaluate the signiﬁcance of all electrophysiological data.
Intracellular injection
VDM 11 (dissolved in Tocrisolve
 ) or Tocrisolve
  itself was injected
into muscle cells within 100 lm of the end plate through a glass
micropipette with a tip diameter less than 0.1 lm. The electrode was
ﬁlledwith7 lmVDM 11(orthecorrespondingvolumeofTocrisolve
 )
and rhodamine B to monitor the progress of the injection. Between 10
and 20 5-s pulses (30 p.s.i.) were applied via a pneumatic pico pump
(PV 830; World Precision Instruments). When VDM 11 was applied
directlytothebathingsolution,itsﬁnalconcentrationwasatleast7 lm.
Calcium imaging
Wide-ﬁeld epiﬂuorescence microscopy was used to measure calcium
transients in motor nerve terminals loaded with the ﬂuorescent Ca
2+
indicatorcalciumgreen-1dextran(MolecularProbes).Calciumgreen-1
dextran (3000 or 10 000 MW) was back-loaded into nerve terminals
using the same technique described previously for loading Texas red
dextran. The imaging was performed on a Nikon Eclipse (TE2000-E)
inverted microscope with a 60· water immersion objective (numerical
aperture 1.0) with an additional 1.5· magniﬁcation for a ﬁnal
magniﬁcation of 90·. A standard ﬁlter cube optimized for ﬂuorescin
isothiocyeuate (FITC) was used. The camera for the imaging experi-
ments was a Cascade 512B cooled charge-coupled device (CCD)
camera (Photometrics, Tucson, AZ, USA) that utilizes impact-ioniza-
tion for low-noise signal gain. Images were acquired as a time lapse (50
or 100 10-ms exposures with a delay of 25 ms between exposures due
to the internal memory transfer and buffering of the camera) and then
compiled into a stack (metamorph v6.3). After collecting ﬁve to six
images, which were used to establish baseline ﬂuorescence, a stimulus
(a suprathreshold 1–10-V square pulse 0.04 ms in duration) was
delivered to the nerve. The stimulus was synchronized with the image
capture by using trigger pulses (generated by metamorph v6.3) and
two Macintosh-driven PowerLab instruments (400 and 4SP, AD
Instruments). The speed of the image acquisition and proper synchron-
ization allowed for the recording of the complete time-course of the
calciumsignal. Thedatawereanalysedbyselectinga singleboutonas a
region of interest and measuring the average light intensity. After
subtracting the average light intensity from a region not associated with
the nerve terminal (i.e. background), the average light intensity was
plotted as a function of time (see Fig. 4C).
Results
CB1 receptors are concentrated on the presynaptic nerve
terminal
Most of the biological effects of cannabinoids are mediated through
speciﬁc membrane receptors. Of the two subtypes that have been
discovered and cloned, the CB1 receptor exists primarily in the nervous
system with the CB2 receptor located mainly in immune tissue
(Howlett et al., 2002; but see Van Sickle et al., 2005). We used
immunoﬂuorescence to determine whether the CB1 receptor is present
at the lizard NMJ. As seen in Fig. 1, we detected considerable staining
with antibodies to the CB1 receptor. To determine speciﬁcally where
the receptors are located at the NMJ, we back-ﬁlled the nerve terminals
with Texas red dextran (see Materials and methods) and processed the
tissue for immunoﬂuorescence, using ﬂuorescein-labelled secondary
antibodies to reveal the CB1 receptors. The results, shown in Fig. 1A,
indicate that CB1 receptors are found mostly on the nerve terminals. We
did observe some CB1 receptor staining that did not colocalize with the
nerve terminal and therefore appears green but most was clearly on the
nerve terminal and therefore appears yellow because it overlays Texas
red dextran. Careful examination of 0.5-lm confocal planes revealed
that most of the CB1 receptors were located along the periphery of the
nerve terminal branches and boutons, presumably associated with the
cell membrane (see arrows in Fig. 1A). As a control, two preparations
were exposed to the secondary antibody without the primary anti-CB1
antibody. No ﬂuorescence could be detected in these preparations.
To further establish the localization of the CB1 receptors, PSCs,
glial cells that closely envelope the nerve terminals, were stained using
the nucleic acid stain POPO
 -3 iodide (Molecular Probes). As the
nerve terminals do not contain nucleic acids, POPO
 -3 uniquely
identiﬁes the PSCs. The tissue was also processed for immunoﬂuo-
rescence, using ﬂuorescein-labelled secondary antibodies to locate the
CB1 receptors. Using confocal microscopy, we determined that a small
amount of CB1 receptors are present on the PSCs. Figure 1B shows six
confocal images collected at 0.5-lm intervals. Although there is a
small amount of overlap between the green (CB1 receptor) and red
(PSCs) signals, a close examination of the individual confocal images
reveals that most of the CB1 receptors do not overlap with the PSCs
but are located above, below or between the PSCs. Our observations
of 12 preparations costained with CB1 antibodies and either POPO
 -3
or Texas red dextran (to identify PSCs or nerve terminals, respect-
ively) allow us to conclude that the CB1 receptors are concentrated in
cell membranes of the motor nerve terminals at the lizard NMJ.
However, our observations do not allow us to exclude the possibility
that some CB1 receptors are expressed on the PSCs. We did not
observe any CB1 immunoﬂuorescence associated with the muscle cells
(data not shown).
M3 and CB1 antagonists block muscarine-induced synaptic
depression
In previous work muscarine has been shown to modulate synaptic
transmission at the lizard NMJ in a biphasic manner, ﬁrst depressing
and then enhancing neurotransmitter release (Graves et al., 2004). In
addition to being temporally separable, the depression and enhance-
ment are also pharmacologically distinct; the M3 mAChR subtype
mediates the depression and the M1 subtype mediates the enhance-
ment (Graves et al., 2004). To determine whether the CB1 receptor
plays a role in either (or both) phase(s), the CB1 antagonist AM 281
was applied. Although AM 281 had no effect when applied by itself
(data not shown), when muscarine was applied in the presence of
AM 281 the ﬁrst phase (depression) was precluded whereas the
second phase (enhancement) was unaffected. Thus, we focused the
remainder of our investigation on the depression of neurotransmission
triggered by muscarine.
Figure 2 depicts the unique pharmacological sensitivity of the ﬁrst
phase of muscarine’s inﬂuence on synaptic transmission. Following
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by 43.4 ± 2.1% (mean ± SEM), which is signiﬁcantly different from
baseline measurements taken prior to muscarine application (P < 0.05;
Fig. 2A, left and C). The M3 receptor antagonist 4-diphenylacetoxy-N-
methylpiperidine methiodide prevents this. In the presence of
4-diphenylacetoxy-N-methylpiperidine methiodide, muscarine reduced
the EPP amplitude by only 4.9 ± 3.0%, a change not signiﬁcantly
different from baseline (Fig. 2C). In a similar manner, in the presence
of the CB1 receptor antagonist AM 281, the EPP amplitude decreased
by only 1.0 ± 5.7%, which is also not signiﬁcantly different from
control (see Fig. 2A, right, B and C). Thus, the depression of synaptic
transmission at the lizard NMJ by muscarine requires functional M3
and CB1 receptors.
The ability of the CB1 antagonist AM 281 to block muscarine-
induced synaptic depression suggests that eCBs mediate this effect. To
test this suggestion, the CB1 agonist ACPA was applied. ACPA
reduced the EPP amplitude by approximately the same amount as
muscarine (39.1 ± 3.2 vs. 43.4 ± 2.1%; Fig. 2C). Furthermore, ACPA
reduces the EPP amplitude over approximately the same time course
as muscarine (compare Fig. 2B with 5B). After 5–10 min exposure to
ACPA, the EPP amplitude was signiﬁcantly different from baseline
(P < 0.05) but not signiﬁcantly different from the EPP amplitude after
5–10 min exposure to muscarine.
To provide further evidence that an eCB mediates the muscarine-
induced depression, preparations were exposed to both muscarine and
ACPA. The EPP amplitude was reduced by a mean of 40.4 ± 1.5%
after 5–10 min exposure to 5 lm muscarine and 10 lm ACPA. The
mean was signiﬁcantly different from baseline measurements
(P < 0.05) but not different from the EPP amplitude in the presence
of either muscarine or ACPA alone. The ability of ACPA to occlude
the effect of muscarine is consistent with muscarine acting via the
release of an eCB that subsequently inhibits synaptic transmission by
activating a presynaptic CB1 receptor.
Cannabinoid-induced synaptic depression is presynaptic
The synaptic depression induced by muscarine has been shown
previously to be of presynaptic origin; the activation of M3 receptors at
the lizard NMJ reduces the evoked release of neurotransmitter (Graves
et al., 2004). To see if the same is true of the cannabinoid agonist
ACPA, spontaneous MEPPs were recorded in three preparations
before and during the application of ACPA. As shown in Fig. 3, the
mean amplitude of MEPPs was unchanged, indicating that the
reduction of the EPP amplitude induced by ACPA (Fig. 2C) must
be due to a decrease in the quantal content of evoked neurotransmitter
release (Del Castillo & Katz, 1954). Although ACPA had no effect on
the MEPP amplitude, it did signiﬁcantly reduce the frequency of
MEPPs (Fig. 3B), which is also consistent with a presynaptic action.
We also note that the time-course of individual MEPPs was unchanged
by ACPA.
Cannabinoids decrease the evoked calcium transient in nerve
terminal
At synapses where it has been possible to make the necessary
measurements, the activation of CB1 receptors has been shown to
reduce the stimulus-induced calcium transient in the presynaptic nerve
terminal (Twitchell et al., 1997; Sullivan, 1999; Schweitzer, 2000;
Kreitzer & Regehr, 2001; Robbe et al., 2001; Brown et al., 2004;
Fig. 1. Immunoﬂuorescence localization of CB1 receptors at the neuromuscular junction (NMJ). (A) Distribution of CB1 receptors is shown in two NMJs in which
the motor nerve terminal is costained with Texas red dextran. Most of the CB1 receptors (green) are seen as yellow as they overlay the nerve terminal (red). The tissue
was prepared as described in Materials and methods and imaged using a Prairie confocal microscope set to collect 25 image planes at 0.5-lm intervals. Every fourth
confocal image is shown proceeding from the top of the collected stack to the bottom (i.e. each image is 2 lm below or above the adjacent image). Arrows point to
areas in which the CB1 receptors are observed around the periphery of presynaptic boutons. (B) CB1 receptors are shown in an NMJ in which the perisynaptic
Schwann cells (PSCs) are costained with POPO
 -3. The relative lack of overlap between the CB1 receptors (green) and PSCs (red) suggests that PSCs express fewer
CB1 receptors than does the nerve. The tissue was prepared as described in Materials and methods and imaged using a Prairie confocal microscope set to collect six
image planes at 0.5-lm intervals. The confocal images shown proceed from top to bottom. The arrow points to a PSC that appears to express CB1 receptor. Scale
bars, 10 lm.
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evidence in some cells that cannabinoids inhibit a step downstream of
Ca
2+ entry (Takahashi & Linden, 2000; Vaughan et al., 2000). To
determine how eCBs inhibit neurotransmitter release at the lizard
NMJ, we measured calcium transients in motor terminals during
stimulus-evoked action potentials. The ﬂuorescent calcium indicator
calcium green-1 (conjugated to dextran, 3000 or 10 000 MW) was
loaded speciﬁcally into motor nerve terminals via anterograde
axoplasmic transport (Fig. 4A). If the dye was prevented from leaking
out of the well directly into the physiological saline with a Vaseline
 
seal, calcium green-1 dextran was observed exclusively in the nerve
terminals (see Fig. 4B).
Presynaptic calcium transients were measured by delivering a single
supra-threshold stimulus to the motor axon while imaging a motor
nerve loaded with calcium green-1 dextran. A typical series of calcium
transients is plotted in Fig. 4C, showing the change in calcium
concentration (as ﬂuorescence emission intensity) before, during and
after the application of the CB1 agonist ACPA. The peaks of the
transients were measured and plotted for each condition (Fig. 4D).
Compared with measurements made in control (i.e. normal) saline,
ACPA (10 lm) reduced the peak calcium concentration by
24.1 ± 4.9%. The mean calcium peak measured in the presence of
ACPA was signiﬁcantly different (P < 0.05) from the mean calcium
peaks measured both before applying ACPA and after washing with
normal saline.
To determine whether a 24% decrease in the peak Ca
2+
concentration is sufﬁcient to decrease neurotransmitter release by
the amount observed when CB1 receptors are activated by ACPA
( 40%, Fig. 2C), we carried out the following experiment. Using
calcium green-1-loaded nerve terminals we determined that we could
lower the evoked calcium transient in the motor nerve terminals by
25 ± 4% (n ¼ 3) by reducing the concentration of Ca
2+ in the
external physiological saline to 1.2 mm (from 2.0 mm), i.e. by
reducing the external Ca
2+ we could reduce the peak of the calcium
transient by the same amount observed when ACPA is applied (in a
solution with a normal Ca
2+ concentration). We then asked whether
such a decrease was sufﬁcient by itself to reduce EPPs by at least
40%. When we reduced the external Ca
2+ concentration to 1.2 mm
while measuring evoked EPPs, the EPP amplitudes dropped by
74 ± 4% (data not shown). Thus, the decrease in the size of the
evoked calcium transient upon application of ACPA is more than
sufﬁcient to account for the observed inhibition of neurotransmitter
release.
Fig.2 .M 3-mediated synaptic inhibition requires activation of CB1 receptors.
(A) Representative end-plate potentials (EPPs) recorded before and after the
application of muscarine (Musc). N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM 281) (5 lm) was
present along with muscarine (5 lm) while recording the EPP traces shown on
the right. Resting membrane potentials were approximately )90 mV. Calibra-
tion bars, 0.5 mV, 2 ms. (B) Time course of EPP amplitudes from two
representative experiments plotted relative to the initial baseline amplitudes.
The application of either 5 lm muscarine alone (grey) or along with 5 lm
AM 281 (black) is indicated by the horizontal bar. Each data point represents
the mean amplitude of eight sweeps. (C) Mean EPP amplitude (presented as
percent of baseline) after 2–10-min applications of muscarine (5 lm)o r
arachidonylcyclopropylamide (ACPA) (10 lm). Muscarine was applied either
alone (n ¼ 4), with the M3 antagonist 4-diphenylacetoxy-N-methylpiperidine
methiodide (4-DAMP) (10 lm, n ¼ 4) or with the CB1 receptor antagonist
AM 281 (5 lm, n ¼ 4). ACPA was applied alone (n ¼ 11) or with muscarine
(5 lm, n ¼ 4). *The mean EPP amplitude is signiﬁcantly different from control
(P < 0.05; Student’s t-test). Error bars represent SEM.
Fig. 3. The cannabinoid agonist arachidonylcyclopropylamide (ACPA) does
not change the amplitude of miniature end-plate potentials (MEPPs) but
decreases their frequency. (A) Sample MEPPs recorded before (left) and after
(right) the application of ACPA (10 lm). Calibration bars, 0.1 mV, 0.5 s.
(B) Data points represent either the mean amplitude (black) or the mean
frequency (grey) of MEPPs recorded during 1-min intervals before and during
the application of ACPA (5 lm), indicated by the black bar. All data are
expressed as a percent of the mean amplitude or frequency before application of
ACPA (i.e. % baseline). Initial MEPP amplitudes and frequencies ranged from
0.5 to 1.5 mVand 0.1–1.0 Hz, respectively. Resting membrane potentials were
at least )80 mV. *Mean is signiﬁcantly different from baseline (P < 0.05;
Student’s t-test).
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nitric oxide
As shown previously, the muscarine-induced depression of ACh
release requires NO (Graves et al., 2004). To see if ACPA has a
similar requirement, muscles were pretreated with the NO synthase
inhibitor L-NAME or the extracellular NO chelator carboxy-PTIO.
Neither L-NAME nor carboxy-PTIO by themselves had an effect on
the EPP amplitude (data not shown). However, when applied in the
presence of L-NAME or carboxy-PTIO, ACPA did not signiﬁcantly
alter the EPP amplitude (a decrease of 1.2 ± 1.9 and 0.7 ± 2.5%,
respectively; Fig. 5). This result suggests that ACPA does indeed
require NO synthesis and diffusion through the extracellular space to
depress synaptic transmission. However, it is also possible that
L-NAME or carboxy-PTIO interfered with ACPA through a mech-
anism not involving NO synthesis or diffusion. To rule out the former
possibility, ACPA was applied along with the NO donor diethylam-
ine⁄NO complex to a preparation that had been pretreated with
L-NAME. As seen in Fig. 5, diethylamine⁄NO complex restores
ACPA’s ability to inhibit synaptic transmission, reducing the EPP
amplitude by 41.4 ± 2.3% (P < 0.05).
Nitric oxide acts via soluble guanylate cyclase and protein
kinase G
To gain further insight into the role of NO in the eCB-mediated
inhibition of neurotransmitter release, we determined whether a
membrane-permeable analogue of cGMP (8-Br-cGMP) could restore
ACPA’s ability to reduce the EPP amplitude in a preparation pretreated
Fig. 4. The CB1 receptor agonist arachidonylcyclopropylamide (ACPA)
reduces the calcium transient in the motor nerve terminal triggered by a single
nerve impulse. (A) Low magniﬁcation image of a preparation loaded with
calcium green-1 dextran. The dye has been loaded into a few axons and made
its way into the nerve terminals. Scale bar, 100 lm. (B) An overlay of the
calcium green-1 dextran ﬂuorescence emission onto an image collected using
differential-interference contrast (Nomarski) optics. Both images were taken
with a 60· water immersion objective (numerical aperture 1.0) and a Coolsnap
camera (Photometrics). Scale bar, 10 lm. (C) Fluorescence emission intensity
is plotted in arbitrary units as a function of time relative to the stimulus pulse
used to elicit an action potential in the motor nerve. Three traces obtained
during the perfusion with normal physiological saline (Control), following the
application of 5 lm ACPA for 5 min (ACPA) and following the wash-out of
ACPA with normal saline for 20 min (Wash). (D) Mean amplitudes of the
calcium transients measured under the three conditions: Control (n ¼ 12),
ACPA (n ¼ 12) and Wash (n ¼ 9). The application of 10 lm ACPA results in
a signiﬁcant (*P < 0.05 Student’s t-test) and reversible decrease in the calcium
transients induced by a single action potential in the motor nerve.
Fig. 5. Arachidonylcyclopropylamide (ACPA)-induced synaptic inhibition
requires nitric oxide. (A) Representative end-plate potentials (EPPs) recorded
before and after the application of ACPA (10 lm). Either Nx-nitro-l-arginine
methyl ester (L-NAME) or L-NAME and diethylamine ⁄ NO complex (DEA-
NO) (traces on the right) were present during the recording of the EPPs. Each
trace represents the average of eight sweeps. Resting membrane potentials were
approximately )90 mV. Calibration bars, 0.5 mV, 2 ms. (B) Time course of
EPP amplitudes from two representative experiments. The application of ACPA
(10 lm) to a neuromuscular junction (NMJ) exposed to either L-NAME (black)
or L-NAME and DEA-NO (grey) is indicated by the horizontal bar. Each data
point represents the amplitude of an average of eight AC-coupled sweeps. (C)
Mean percent reduction of EPP amplitudes (from initial baseline readings)
following 5–10 min of ACPA (10 lm) application. ACPA was applied either
alone (n ¼ 11), with L-NAME (0.3 mm, n ¼ 5), with 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt (C-PTIO)
(40 lm, n ¼ 4) or with L-NAME and DEA-NO (0.1 mm, n ¼ 5). *The mean
EPP amplitude is signiﬁcantly different from when it was measured under
baseline conditions (P < 0.05; Student’s t-test). Baseline measurements were
made either under control conditions, in the presence of L-NAME, in the
presence of C-PTIO or in the presence of L-NAME and DEA-NO, as
appropriate for the experiment. Error bars represent SEM.
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was just as effective as diethylamine⁄NO complex in overcoming the
block of NO synthase by L-NAME, reducing the EPP amplitude by
43.7 ± 4.3% (P < 0.05). This suggests that NO mediates its
permissive effect by activating soluble guanylate cyclase. To test this
idea further, the soluble guanylate cyclase inhibitor ODQ was applied
15 min before adding ACPA. In the presence of ODQ, ACPA did not
have a signiﬁcant effect on the EPP amplitude (an increase of
3.3 ± 3.4%). To verify the speciﬁcity of ODQ’s effect, 8-Br-cGMP
was shown to reconstitute ACPA’s inhibition of synaptic transmission
in the presence of ODQ (a decrease of 47.3 ± 3.5%, P < 0.05),
presumably by bypassing the blocked soluble guanylate cyclase
enzyme. Lastly, we tested whether cGMP-dependent protein kinase
was necessary. As shown in Fig. 6, Rp-B-Phenyl-1, N
2-etheno-8-
bromoguanosine 3’,5’-cyclic monophosphorothioate (Rp-8-Br-PET-
cGMPS), an inhibitor of cGMP-dependent protein kinase, also
prevented ACPA from altering synaptic transmission (the EPP
amplitude was decreased by 4.8 ± 5.5%).
Phospholipase C and diacylglycerol lipase are required for the
muscarine-induced depression of synaptic transmission
The two most well-studied eCBs, anandamide and 2-AG, are known
to be synthesized from phospholipid precursors in the cell membrane
(Freund et al., 2003). Two main routes of synthesis have been
postulated for 2-AG, one of which involves the ubiquitous enzyme
phospholipase C (PLC) and diacylglycerol lipase (DGL) (Stella et al.,
1997). To ascertain whether 2-AG is involved in the muscarine-
induced depression of ACh release, muscarine was applied to 12
nerve–muscle preparations that had been preincubated for at least 1 h
with the PLC inhibitor U-73122. Under these conditions, muscarine
reduced the EPP amplitude by a mean of only 15.7 ± 3.6%, which is
signiﬁcantly different from the decrease caused by muscarine alone
(P < 0.01; Fig. 7B). However, when the CB1 agonist ACPA was
applied to the same preparations that had been pretreated with
U-73122, the EPP amplitude was decreased by an amount
(53.8 ± 5.2%) that is indistinguishable from the effects of either ACPA
or muscarine in the absence of U-73122 (compare Fig. 7B with Fig. 2).
As the synthesis of 2-AG via the pathway shown in Fig. 7A requires
the enzyme DGL in addition to PLC, we also examined the effects of
the DGL inhibitor RHC-80267. In ﬁve preparations preincubated for
1 h with RHC-80267, muscarine reduced the EPP amplitude by a
mean of 20.9 ± 3.6%, which is also signiﬁcantly different from the
Fig. 6. Nitric oxide (NO) is required to increase cGMP synthesis and activate
protein kinase G. (A) The NO-cGMP signalling pathway. NO-stimulated
soluble guanylyl cyclase (sGC) and cGMP-dependent protein kinase-1 (PKG).
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) is an inhibitor of sGC,
Rp-B-Phenyl-1, N
2-etheno-8-bromoguanosine 3’,5’-cyclic monophosphor-
othioate (Rp-8-Br-PET-cGMPS) is an inhibitor of PKG and 8-Br-cGMP is a
membrane-permeable analogue of cGMP. (B) Mean percent reduction of end-
plate potential (EPP) amplitudes following application of arachidonylcyclo-
propylamide (ACPA) (10 lm). ACPA was applied with Nx-nitro-l-arginine
methyl ester (L-NAME) (0.3 mm) and 8-Br-cGMP (40 lm, n ¼ 6) with ODQ
(50 lm, n ¼ 4), ODQ and 8-Br-cGMP (n ¼ 4) and Rp-8-Br-PET-cGMPS
(30 lm, n ¼ 4). *The mean EPP amplitude is signiﬁcantly different from its
measurement under baseline conditions (P < 0.05; Student’s t-test). Baseline
EPP measurements were made in the presence of L-NAME and 8-Br-cGMP,
ODQ, ODQ and 8-Br-cGMP, or Rp-8-Br-PET-cGMPS, respectively. Error bars
represent SEM.
Fig. 7. Endocannabinoids are produced through a phospholipase C (PLC)-
and 1,2-diacylglycerol (DAG)-mediated pathway. (A) Biosynthetic pathway
for 2-arachidonoylglycerol (2-AG). PI, phosphatidylinositol; DGL, diacylglyc-
erol lipase. (B) Mean percent reduction of end-plate potential (EPP) amplitude
following application of muscarine (Musc.) (5 lm). Muscarine was applied
alone (n ¼ 5), with the PLC inhibitor 1-[6-[[(17b)-3-methoxyestra-1,3,4(10)-
trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-73122) (5 lm, n ¼ 12),
with U-73122 and arachidonylcyclopropylamide (ACPA) (n ¼ 4), with the
DGL inhibitor 1,6-bis-(cyclohexyloximinocarbonylamino)-hexane (RHC-
80267) (200 lm, n ¼ 5), and with RHC-80267 and ACPA (n ¼ 3). All of
the means were signiﬁcantly different from baseline measurements made under
control conditions (P < 0.05; Student’s t-test). The Student’s t-test was also
used to calculate the statistical signiﬁcance of the differences between each
individual mean. None of the differences were signiﬁcant except for those
indicated on the graph. Error bars represent SEM.
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likelihood that the action of RHC-80267 was due speciﬁcally to its
inhibition of DGL was demonstrated by applying 10 lm ACPA to
preparations that had been pretreated with RHC-80267 (and musca-
rine) and showing that ACPA still inhibited the EPP amplitude by its
normal amount (i.e. 50.1 ± 5.9%).
Although the comparisons described above indicate that the
enzymes PLC and DGL are responsible for a statistically signiﬁcant
component of the muscarine-inducued depression, it is noteworthy
that muscarine still signiﬁcantly reduced (P < 0.05) the EPP
amplitude in the presence of either U-73122 or RHC-80267 (see
Fig. 7).
Endocannabinoids are released from the muscle via an
endocannabinoid membrane transporter
Evidence has recently been presented that eCBs are released from
striatal neurones in the rat brain by a membrane transporter that acts
via facilitated diffusion (Ronesi et al., 2004). To determine whether
the same mechanism might be responsible for eCB release at the
lizard NMJ and to establish the cellular source of the eCBs, we
injected individual muscle cells with VDM 11, an inhibitor of eCB-
facilitated diffusion (De Petrocellis et al., 2000). Shortly after
injecting VDM 11, EPPs were recorded from the same muscle ﬁbre
before and after the local application of muscarine. The average EPP
amplitude was not signiﬁcantly changed under these conditions
(Fig. 8). In contrast, when muscles were injected with Tocrisolve
 ,
the solvent in which VDM 11 was dissolved, or if VDM 11 was
added to the bathing solution, muscarine signiﬁcantly inhibited the
EPP amplitude (by 58.1 ± 1.2 and 49.6 ± 8.2%, respectively; Fig. 8).
In contrast to muscarine, when the CB1 receptor agonist ACPA was
applied to muscle cells injected with VDM 11, the EPP amplitude
was signiﬁcantly depressed (45.8 ± 8.9%; Fig. 8). The only condi-
tion under which the EPP amplitude was not signiﬁcantly inhibited
was when muscarine was applied to muscles that had been injected
with VDM 11. The small reduction of the EPP amplitude
(10.9 ± 3.7%) was signiﬁcantly different from each of the other
conditions (P < 0.01; Fig. 8). These results collectively support the
suggestion that eCBs are released from the postsynaptic muscle cells
via facilitated diffusion (Ronesi et al., 2004). These results also
indicate that the muscle is the source of eCBs released at the
vertebrate NMJ following the activation of M3 mAChRs.
Endocannabinoids are involved in synaptic depression
The preceding experiments point to an essential role for eCBs in the
inhibition of synaptic transmission following the activation of M3
mAChRs. To determine the physiological context under which eCBs
might become deployed, we looked for an effect of the CB1 receptor
antagonist AM 281 on a form of synaptic depression that most
closely resembles the magnitude and time-course of the inhibition
induced by either muscarine or ACPA. The results are shown in
Fig. 10. Continuous stimulation of the motor nerve at 1 Hz for
20 min depresses the EPP amplitude by 38.2 ± 9.2%, a reduction
that is not signiﬁcantly different from that produced by either
muscarine or ACPA (see Fig. 2). In the presence of AM 281,
however, stimulation of the motor nerve (20 min, 1 Hz) failed to
depress synaptic transmission, resulting in a mean EPP amplitude
that is 120.7 ± 15.3% of baseline, an amplitude that is signiﬁcantly
different from that produced in the absence of AM 281 (P < 0.05;
Fig. 10).
Discussion
To our knowledge, this is the ﬁrst report of cannabinoid receptors at a
vertebrate striated NMJ. Although the CB1 receptor has been
identiﬁed throughout the central and peripheral nervous systems in
several species (see Howlett et al., 2002) and its effects have been
detected at the frog NMJ (Turkanis & Karler, 1986; Van der Kloot,
1994), the receptor has never been localized speciﬁcally at the NMJ of
any species. Our observation that CB1 receptors are concentrated on
the motor nerve terminals is consistent with its preferential expression
on presynaptic nerve terminals elsewhere in the nervous system (see
Kreitzer & Regehr, 2002; Wilson & Nicoll, 2002). However, our
immunoﬂuorescence studies also suggest that CB1 receptors may be
on the closely associated PSCs, albeit at a lower density (Fig. 1B). The
signiﬁcance of this observation has yet to be explored.
Fig. 8. Intracellular injection of cannabinoid transport inhibitor
(5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide
(VDM 11) into the muscle blocks muscarine-induced depression. (A) Micro-
graphs showing the injection of VDM 11 into a muscle ﬁbre near an end plate.
The image on the left was collected during the pressure injection of VDM 11
and rhodamine B. The neuromuscular junction (NMJ) was stained with
tetraethylrhodamine-a-bungarotoxin and can be seen just below and to the right
of the injection electrode (arrow). A faint image of the recording electrode can
also be seen approaching from the right (highlighted by dashed lines). The
image on the right was collected 5 min after injecting the muscle ﬁbre. The
injection electrode has been removed from the ﬁeld of view and the
extracellular pipette used to apply muscarine has been moved into position
just below the neuromuscular junction. (B) Mean percent reduction of end-plate
potential (EPP) amplitudes following the local application of muscarine or
arachidonylcyclopropylamide (ACPA). Muscarine was applied to NMJs
injected with the solvent Tocrisolve
  (n ¼ 3) or with VDM 11 dissolved in
Tocrisolve
  (n ¼ 6). ACPA was applied to NMJs injected with VDM 11
(n ¼ 8). Muscarine was also applied to NMJs bathed in VDM 11 (n ¼ 4). The
Student’s t-test was used to calculate the statistical signiﬁcance of the
differences between the indicated pairs of means.
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previous work had shown that: (i) activation of M3 mAChRs depresses
neurotransmitter release at this synapse (Graves et al., 2004) and (ii)
eCBs mediate a similar suppression of neurotransmitter release
induced by M3 receptor activation in the hippocampus (Fukudome
et al., 2004). The results reported here suggest that eCBs play a similar
role at these two synapses. The model presented in Fig. 9 summarizes
the role of eCBs at the vertebrate NMJ suggested by the experiments
described in this work. Activation of M3 receptors on the muscle cell
triggers the synthesis of eCBs, probably 2-AG, that are released via a
transporter in the muscle membrane. Once in the synaptic cleft, 2-AG
binds to CB1 receptors on the presynaptic nerve terminal, reduces the
action-potential-induced Ca
2+ transient and thereby reduces neuro-
transmitter release. NO, produced in either the muscle or PSCs, is
required for one or more of the steps depicted in Fig. 9.
Mechanism of action of endocannabinoids
Previous studies are consistent with our conclusion that eCBs suppress
synaptic transmission presynaptically (Kreitzer & Regehr, 2002;
Wilson & Nicoll, 2002) and by decreasing the calcium transient in the
presynaptic nerve terminal. In some neurones, cannabinoids have been
shown to inhibit presynaptic voltage-dependent Ca
2+ channels (e.g.
see Kushmerick et al., 2004). In other neurones, cannabinoids have
been found to activate presynaptic K
+ channels (e.g. Schweitzer, 2000;
Robbe et al., 2001; Daniel et al., 2004). In either case, cannabinoids
reduce the depolarization-induced Ca
2+ transient in the presynaptic
terminal (see Kreitzer & Regehr, 2001) and thereby decrease the
release of neurotransmitter. Our results are consistent with either
possibility; future work will be necessary to elucidate the speciﬁc
mechanism at the NMJ.
Our observation that the cannabinoid agonist ACPA reduces the
frequencyofMEPPs(seeFig.3)hasbeenreportedbyothers(Takahashi
& Linden, 2000; Vaughan et al., 2000; Gerdeman & Lovinger, 2001).
Such observations have been used to support a mechanism of action for
cannabinoids that is downstream of Ca
2+ inﬂux, i.e. a direct action on
the secretory machinery. This appears to conﬂict with most investiga-
tions, including the present one (Fig. 4C and D), which have reported
that activation of CB1 receptors causes a signiﬁcant reduction in
presynaptic Ca
2+ inﬂux (Brown et al., 2004; Twitchell et al., 1997;
Sullivan, 1999; Schweitzer, 2000; Kreitzer & Regehr, 2001; Robbe
et al., 2001; Daniel et al., 2004; Kushmerick et al., 2004). These
Fig. 9. Proposed model summarizing the role played by endocannabinoids (eCBs) at the vertebrate neuromuscular junction. This represents our current working
model for explaining the signalling pathways involved in muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Block arrows represent
the diffusion or movement of a signalling molecule. Curved block arrows indicate an enzymatic conversion. Solid black arrows depict steps that have been
experimentally veriﬁed, whereas dashed arrows reveal steps that contain unknown details. All chemicals in italics and their respective arrows are meant to show the
various targets of each of the experimental reagents used (see text for details). We are not sure whether nitric oxide (NO) is produced in the muscle ﬁbers or the
perisynaptic Schwann cells so we have included each possibility and noted both with an asterisk. NO, acting via cGMP-dependent protein kinase (PKG), is necessary
but not sufﬁcient to modulate neurotransmitter release and we have noted this with a dashed line and & symbol. We do not yet know the speciﬁc target of PKG.
D[Ca
2+]i, intracellular calcium transient; ACh, acetylcholine; ACPA, arachidonylcyclopropylamide; 2-AG, 2-arachidonylglycerol; AM 281, N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; CB1, cannabinoid receptor subtype 1; cGMP, cyclic guanosine monophosphate; DAG,
diacylglycerol; 4-DAMP, 4-diphenylacetoxy-N-methylpiperidine methiodide; DGL, diacylglycerol lipase; G, G-protein; GTP, guanosine triphosphate; L-NAME,
Nx-nitro-l-arginine methyl ester; M3, muscarinic acetylcholine receptor subtype 3; nAChR, nicotinic acetylcholine receptor; NOS, NO synthase; ODQ,
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; PI, phosphatidylinositol or its phosphorylated derivatives; PLC, phospholipase C; RHC-80267, 1,6-bis-(cyclohexyl-
oximinocarbonylamino)-hexane; Rp-8-Br-PET-cGMPS; sGC, soluble guanylate cyclase; U-73122, 1-[6-[[(17b)-3-methoxyestra-1,3,4(10)-trien-17-yl]amino]hexyl]-
1H-pyrrole-2,5-dione; VDM 11, (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide.
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eCBs. Alternatively, they may reﬂect different degrees of coupling
between calcium channels and the presynaptic vesicle release complex
(e.g. see Spafford & Zamponi, 2003). We have not yet investigated this
further; however, the vertebrate NMJ is ideal for answering such
mechanistic questions and we eagerly anticipate using this preparation
to clarify such questions related to eCB-mediated synaptic modulation.
Requirement for nitric oxide
Inadditionto beingthe ﬁrstdescription ofa physiologicalrolefor eCBs
at the vertebrate NMJ, this is also the ﬁrst time that the mechanism of
action of eCBs has been directly shown to depend on NO (see Fig. 5).
There have been numerous reports suggesting a linkage between eCBs
andNO(e.g. seeRandall &Kendall,1998;Waksman etal.,1999;Azad
et al., 2001; Namiki et al., 2005); however, to our knowledge, the
cellular mechanism of action of eCBs in the nervous system has never
been linked to an absolute requirement for NO. The dependence of
eCBs on NO reported in this work may be unique to the NMJ.
Alternatively, it may be a more general phenomenon that has not been
considered elsewhere. Our results indicate that eCB-mediated synaptic
modulation requires NO; however, as shown previously for muscarine-
induced synaptic modulation (Graves et al., 2004), NO is necessary but
not sufﬁcient. The observation that NO synthase is present in all three
cellular components at the NMJ, the nerve terminal, muscle and PSC
(Graves et al., 2004),makes itdifﬁcult to determine the essential source
of NO. However, we do know that NO must be synthesized in a
different cell than its target as chelating extracellular NO with carboxy-
PTIO abolishes synaptic modulation (Fig. 5). Therefore, we postulate
that NO is synthesized in the muscle or PSC and diffuses to the nerve
terminal where it activates soluble guanylate cyclase (see Fig. 9).
Evidence obtained at the amphibian NMJ supports the suggestion that
the muscle is the source of NO, which is generated either tonically
(Thomas & Robitaille, 2001) or in response to indirect low-frequency
stimulation (Etherington & Everett, 2004).
Evidence that 2-arachidonoylglycerol is responsible for
muscarine-induced depression
Our results implicate 2-AG as the eCB at the vertebrate NMJ (Fig. 7).
It is worth noting that we were unable to completely abolish
muscarine-induced synaptic depression by inhibiting PLC or DGL
(compare Figs 2 and 7). This either means that the inhibitors that we
used, U-73122 and RHC-80276, did not fully eliminate the activity of
PLC and DGL or that there is another pathway for synthesizing eCBs
at the lizard NMJ. In addition to using PLC and DGL, phosphatidy-
linositol can also be converted to 2-AG via phospholipase A1 and
lyso-PLC (Freund et al., 2003). Thus, the residual synaptic depression
observed in Fig. 7 may have been due to the synthesis of 2-AG via this
latter pathway (not shown). It is also possible that another cannabi-
noid, such as anandamide, is also released by the activation of M3
receptors at the NMJ. Additional experiments are needed to distin-
guish between these possibilities.
Mechanism of endocannabinoid release at the vertebrate
neuromuscular junction
Regardless of whether the eCB at the vertebrate NMJ is exclusively
2-AG or is 2-AG and anandamide, it is clear from this study that the
eCB is synthesized in the muscle and is released by a membrane
transporter (see Fig. 8). The idea of injecting VDM 11 in the muscle
was inspired by Ronesi et al. (2004) who had shown that injection of
VDM 11 into postsynaptic cells in corticostriatal brain slices from the
rat abolished a long-term depression known to involve eCBs. As noted
by Ronesi et al. (2004), the transporter previously shown to be
responsible for the uptake of anandamide and 2-AG via the process of
facilitated diffusion (Beltramo et al., 1997; Hillard et al., 1997) would
also be able to transport either eCB out of the cell. The net direction of
the movement would simply depend on the relative concentration of
eCB across the membrane. Thus, in a cell such as a striatal neurone or a
vertebrate muscle in which eCBs are rapidly synthesized, the
transporter will function to release the eCBs into the surrounding synaptic
gap. We believe that this is what is happening at the vertebrate NMJ.
Physiological relevance of endocannabinoids at the vertebrate
neuromuscular junction
Under physiological conditions the muscarinic receptors at the
vertebrate NMJ are presumably activated by ACh released from the
motor nerve terminal during the process of synaptic transmission. The
results presented here suggest that 20 min of 1-Hz stimulation is
sufﬁcient to activate the release of eCBs, which then depress synaptic


















































Fig. 10. Synaptic depression requires functional CB1 receptors. (A) Time course of end-plate potential (EPP) amplitudes from two representative experiments in
which the motor nerve was stimulated for 20 min at 1 Hz (indicated by the horizontal hatched bar). The experiment was performed either under control conditions
(black) or in the presence of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM 281) (grey). Each data point
represents the amplitude of an average of eight sweeps. (B) Mean percent reduction of EPP amplitudes (from initial baseline readings) following 20 mino f
continuous 1-Hz stimulation of the motor nerve. Stimulation was delivered either under control conditions (n ¼ 11) or in the presence of AM 281 (1 lm; n ¼ 7).
The mean EPP amplitudes under these two conditions are signiﬁcantly different from each other (P < 0.05; Student’s t-test). Baseline measurements were either
made under control conditions or in the presence of AM 281, as appropriate for the experiment. Error bars represent SEM.
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logical results presented in this work, is that ACh activates M3
mAChRs, which then elicits the synthesis (Fig. 7) and release (Fig. 8)
of eCBs. However, there are other possibilities. Glutamate, which has
been shown to be involved in synaptic depression at the frog NMJ
(Pinard et al., 2003), may be responsible for the release of eCBs under
physiological conditions. Under certain circumstances, glutamate may
act either with or without ACh. Further experiments are needed to
resolve these possibilities.
Conclusion
Given the apparent high density of CB1 receptors on motor nerve
terminals (e.g. Fig. 1A) and the relatively robust physiological effects
of CB1 agonists and antagonists (e.g. Figs 2, 3 and 5), we ﬁnd it
surprising that it has taken so long for a role to be discovered for eCBs
at the vertebrate NMJ. This is even more surprising given the fact that
it has been known for many years that exogenous cannabinoids reduce
motor function in rats (Compton et al., 1996; Romero et al., 1996) and
humans (Ashton, 1999). We hope that the results presented in this
work will stimulate further investigation into the role of eCBs at the
NMJ. In addition to providing a greater appreciation of the diversity of
roles for eCBs, the results reported here indicate that the vertebrate
NMJ, which is an excellent model synapse for investigating the
cellular and molecular details of synaptic transmission, may be
employed to great advantage in studying details of eCB physiology.
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